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Abstract 
Background: Recent vaccine studies have shown that the magnitude of an antibody response is often insufficient 
to explain efficacy, suggesting that characteristics regarding the quality of the antibody response, such as its fine 
specificity and functional activity, may play a major role in protection. Previous studies of the lead malaria vaccine 
candidate, RTS,S, have shown that circumsporozoite protein (CSP)‑specific antibodies and CD4+ T cell responses are 
associated with protection, however the role of fine specificity and biological function of CSP‑specific antibodies 
remains to be elucidated. Here, the relationship between fine specificity, opsonization‑dependent phagocytic activity 
and protection in RTS,S‑induced antibodies is explored.
Methods: A new method for measuring the phagocytic activity mediated by CSP‑specific antibodies in THP‑1 cells 
is presented and applied to samples from a recently completed phase 2 RTS,S/AS01 clinical trial. The fine specificity 
of the antibody response was assessed using ELISA against three antigen constructs of CSP: the central repeat region, 
the C‑terminal domain and the full‑length protein. A multi‑parameter analysis of phagocytic activity and fine‑specific‑
ity data was carried out to identify potential correlates of protection in RTS,S.
Results: Results from the newly developed assay revealed that serum samples from RTS,S recipients displayed a 
wide range of robust and repeatable phagocytic activity. Phagocytic activity was correlated with full‑length CSP 
and C‑terminal specific antibody titres, but not to repeat region antibody titres, suggesting that phagocytic activ‑
ity is primarily driven by C‑terminal antibodies. Although no significant difference in overall phagocytic activity was 
observed with respect to protection, phagocytic activity expressed as ‘opsonization index’, a relative measure that 
normalizes phagocytic activity with CS antibody titres, was found to be significantly lower in protected subjects than 
non‑protected subjects.
Conclusions: Opsonization index was identified as a surrogate marker of protection induced by the RTS,S/AS01 vac‑
cine and determined how antibody fine specificity is linked to opsonization activity. These findings suggest that the 
role of opsonization in protection in the RTS,S vaccine may be more complex than previously thought, and demon‑
strate how integrating multiple immune measures can provide insight into underlying mechanisms of immunity and 
protection.
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Background
Immunity to the pre-erythrocytic stage of Plasmodium is 
considered the most promising target for malaria vaccine 
development. The resulting protection is typically sterile, 
i.e., it prevents blood-stage infection and, thus, the onset 
of symptoms and blocks transmission of the parasites to 
other individuals. Most sporozoites egress from the skin 
into either the lymphatics or the blood stream after being 
injected into the skin by the mosquito during a blood 
meal (reviewed in [1]). The main target of anti-sporozoite 
antibodies is the circumsporozoite protein (CSP), which 
is the most abundantly expressed protein on the surface 
of the sporozoite. CSP has been the leading vaccine anti-
gen for decades, albeit with variable success depending 
on the vaccine platform [2–5]. RTS,S/AS01, currently 
the lead recombinant vaccine candidate against malaria, 
is based on a pseudoparticle consisting of the hepatitis B 
surface antigen and a large fragment of the CSP, namely 
the central repeat region and the C-terminus of the pro-
tein. While only a few correlates of protection are known 
for most of the human vaccines (reviewed in [6]), it is 
becoming increasingly apparent that antibodies to the 
repeat region in RTS,S are associated with protection 
against malaria [7]. Whether or not they are only sur-
rogate markers or true correlates of protection remains 
to be determined, and the mechanisms by which sporo-
zoite-specific antibodies may mediate protection is still 
not known. There have been significant advancements 
in the understanding of antibody-mediated immune 
functions in the last few years. Until recently, the main 
emphasis was placed on measuring the magnitude of an 
antigen-specific antibody response. This does not take 
into account the quality of the humoral response in the 
form of antibody avidity and isotype, as well as epitope 
specificity. Functional antibody assays can address the 
question whether immune complexes bind to cellular 
receptors and trigger phagocytosis. This process results 
in the uptake, degradation of antigenic/pathogenic mate-
rial and subsequent antigen-presentation to adaptive 
immune cells [8, 9].
Although it has been shown that anti-CSP repeat 
region antibodies are necessary for the protection elic-
ited by RTS,S/AS01, subsequent clinical trials have 
shown that the magnitude of the anti-CSP repeat region 
antibody response is only weakly associated with pro-
tection [7, 10–13]. One explanation for this apparent dis-
crepancy is that the quantity of anti-CSP repeat region 
antibodies in an antibody response may only serve as a 
surrogate marker for its functional capacity to neutralize 
the Plasmodium parasite. One possible hypothesis is that 
protection induced by the RTS,S vaccine is mediated by 
opsonization and phagocytosis. The uptake of opsonized 
parasites by phagocytic cells can lead to several possible 
outcomes, including phagocytosis, destruction of the 
parasite, followed by antigen presentation to T lympho-
cytes, or phagosomal escape of the parasite, which then 
resides in the phagocytic cell. The latter would constitute 
an immune escape mechanism. Although opsonization 
and phagocytosis have, to date, been poorly character-
ized in pre-erythrocytic stage immunity, this has been 
studied previously for blood-stage parasites and found to 
be associated with natural immunity to clinical malaria 
[14, 15], underscoring its potential role in protection for 
malaria vaccines.
The aim of the present study was to directly measure 
antibody-mediated opsonic phagocytic activity and iden-
tify how the fine specificity of the antibody response, 
defined as the relative response to individual epitope 
regions of the CS antigen, is associated with opsoniza-
tion activity and protection. Towards that end, a highly 
sensitive, high-throughput assay to measure the phago-
cytic activity mediated by antibodies was developed and 
applied to human sera from subjects vaccinated with the 
RTS,S vaccine. The flow cytometry-based assay uses anti-
gen-coated fluorescent beads to determine the frequency 
and intensity of phagocytosis by immune cells. This assay 
represents a significant improvement over a previous 
attempt to quantify CSP antibody-mediated opsonization 
due to its increased sensitivity, which allows for the iden-
tification of distinct populations of cells based on their 
phagocytic activity. Furthermore, unlike previous studies 
that measure opsonization using fluorescently labelled 
parasites [15, 16], the method described here can be per-
formed by any laboratory without the need to have access 
to parasites.
The present study characterizes sera from subjects 
immunized in a phase 2 study using the standard RTS,S/
AS01-vaccination regimen (three doses in four-week 
intervals). The efficacy of the trial, and the basic immu-
nological evaluation have previously been reported [10]. 
The first step in the analysis was to measure the abil-
ity of the RTS,S/AS01-induced antibodies to opsonize 
CSP-coated fluorescent beads and mediate uptake by 
phagocytic cells. Next, the data was stratified based on 
the protective status of the individuals following the 
controlled challenge with infectious mosquitoes. No 
significant difference in overall phagocytic activity with 
respect to protection was observed. However, relative 
phagocytic activity, measured as ‘opsonization index’, was 
found to be associated with protection—protected sub-
jects, surprisingly, had lower opsonization efficiency, than 
non-protected subjects. An in-depth analysis of the fine 
specificity of RTS,S/AS01-induced antibodies suggested 
that it was antibodies targeting the C-terminal region of 
CSP, and not the repeat region, that were associated with 
phagocytic activity, and that antibody responses from 
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protected individuals in this study were characterized by 
higher repeat-specific antibody titres and lower opsoni-
zation activity. Given the limited sample size in this 
study (n = 20), further research on the role of phagocytic 
activity on protection in the RTS,S-induced antibody 
response is warranted, however, this study demonstrates 
how the combined analysis of multiple in vitro functional 
assays can yield insight into the mechanisms that under-




Samples were obtained from one of the vaccine cohorts 
of clinical study NCT01366534 [10]. The efficacy of 
the trial, and the basic immunological evaluation have 
previously been reported [7]. Sera from all 20 subjects 
in the cohort that was vaccinated with three doses of 
RTS,S/AS01 on a zero–one–two-month schedule were 
tested for functional activity in the phagocytosis assay. 
Ten of the tested 20 subjects were protected in a con-
trolled human malaria infection challenge allowing 
the stratification of the data with respect to protec-
tive status. Experiments were reviewed and approved 
by the GSK-MVI Correlates of Protection Task Force. 
All study participants had previously provided con-
sent for future use of the samples for research. Con-
sent to publish was not required as the samples were 
de-identified.
ELISA assay for CS fine specificity
The ELISA assay was performed in the Malaria Serol-
ogy Laboratory (USMMRP, WRAIR Silver Spring, USA) 
employing full-length CSP, NANP peptide and C-ter-
minal peptide (PF16) as plate antigens as previously 
described [17, 18]. ELISA titres are listed as endpoint 
dilution at an optical density (OD) of 1.
Phagocytosis
Phagocytosis was assessed by measuring the uptake of 
CSP-coated fluorescent beads by THP-1 cells. THP-1 is 
a human monocytic cell line that serves as an in  vitro 
model for phagocytosis mediated by Fc receptors and 
complement receptors (reviewed in [19]). THP-1 cells 
were cultured in 75-sq cm flasks at a density of ≤5 × 105 
cells/ml for not more than 30 passages (about 8 weeks). 
NeutrAvidin-coated fluorescent beads (1 µm size, exci-
tation/emission  =  488/530  nm, Molecular Probes, 
Eugene, OR, USA) were incubated with biotinylated 
CSP [20] at 4  °C overnight. THP-1 cells are plated at 
2  ×  105 cells/ml in 24-well plates the day before the 
assay. Beads were washed with PBS +  1  % BSA (wash 
buffer) and aliquots incubated with serially diluted sera 
(1:100, 1:500, 1:2500, 1:12,500, 1:62,500) for 2 h at 4 °C 
and then added to the THP-1 for 45  min (37  °C). The 
ratio of cells to beads had been previously optimized to 
100 beads per THP-1 cell. Activity observed with the 
pre-immune serum (1:100 dilution) was used to deter-
mine the (non-specific) background activity for each 
study subject. Cells were transferred to FACS tubes 
on ice and centrifuged for 5  min and the data were 
acquired on a FACSCalibur (CellQuest software, Bec-
ton–Dickinson, Mountain View, CA, USA). The level 
of phagocytosis was determined by applying markers to 
the histograms. The marker M1 measures all fluorescent 
cells; M2 reports cells that have taken up ≥2 beads. The 
frequency of cells that underwent phagocytosis (Mfreq) 
and the mean fluorescence intensity of cells that under-
went phagocytosis (MFI), related to the number of 
beads taken up, for M2 cells, is reported.
Data analysis
The opsonization titre as the serum dilution that leads to 
60 % of peak opsonization activity using either the Mfreq 
or MFI measures is reported. At each dilution point, the 
Mfreq and MFI measure was recorded in the M2 condi-
tion. For each opsonization measure (Mfreq and MFI), 
and for each subject, a four-parameter logistic fit model 
was used (Eq.  1) that assumes a symmetric sigmoidal 
curve to fit the opsonization activity (Ops) versus serum 
dilution (log[Ab]) data and uses that fitted curve to cal-
culate the serum dilution at 60 % maximal opsonization 
activity (maxOps), as shown in Eq.  2. For each opsoni-
zation measure, the opsonization activity of the undi-
luted pre-immune sample for each subject was used as 
background opsonization activity, and subtracted from 
the opsonization activity at each dilution point, prior to 
calculating the opsonization titres. The dilution at 60  % 
maximal opsonization was used because for a small num-
ber of subjects, there was sufficiently high opsonization 
activity at even the highest dilution that a lower opsoni-
zation activity (such as 50  % of the maximum) would 
be outside the range of the data. Because there are two 
measures for opsonization activity (Mfreq and MFI), two 
independent opsonization titres for each subject were 
calculated.
(1)
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The ratio of endpoint ELISA antibody titres to two 
antigens was calculated as a surrogate measure of the 
fine specificity, or the relative antibody response between 
them (Eq.  3). The following fine specificity ratios were 
calculated: NANP:CS, PF16:CS and PF16:NANP. Finally, 
the relative opsonization activity of a serum sample was 
reported as the opsonization titre of a serum sample nor-
malized by the ELISA titre to full-length CS, referred to 
as the opsonization index (Eq 4). Because there are two 
measures of opsonization activity (Mfreq and MFI) two 
opsonization indices were calculated for each subject.
Statistics
Statistical significance was assessed using an unpaired 
Student’s t test, assuming unequal variances between pro-
tected and non-protected subjects. 1-factor and 2-factor 
analyses of variance (ANOVA) were carried out between 
protected and non-protected subjects. To describe cor-
relations between measures, the square of the Pearson 
correlation coefficient (R2), and p value, following linear 
fitting, were reported. All fitting and statistical analysis 
was carried out using the R statistical package.
Results
Fine specificity of CS‑specific antibody response
Previously, antibody responses to the NANP-repeat 
region of the CS protein in a recent clinical trial of 
RTS,S/AS01 was found to be significantly higher in pro-
tected subjects than in non-protected subjects [10]. In 
the current study, the fine specificity of the CS antibody 
response was characterized in terms of the response 
to the entire full-length CS antigen, to the C-terminal 





(4)Ops index = log
Ops titer
CS titer
region, as well as the previously reported response to the 
central NANP repeat region. ELISA assays were carried 
out using recombinant full-length CS [20] and the C-ter-
minus-representing PF16 peptide [18] (Fig. 1), along with 
the results for the NANP peptide. While, in accordance 
with previous findings, the magnitude of the antibody 
response to the NANP repeat region was associated with 
protection, no significant difference between the anti-
body response to full-length CSP or to the C-terminal 
region was found between protected and non-protected 
subjects. This suggests that the fine specificity of the anti-
body response, and not just its magnitude, is associated 
with protection.
Next, the relationship between antibodies specific for 
distinct regions of CSP, the central repeat (NANP) and 
the C-terminus (represented by the PF16 peptide) ver-
sus the full-length protein was investigated. As expected, 
a correlation between the antibody titres to the NANP 
repeat and PF16 peptide with the full-length CSP titres 
was observed, demonstrating that subjects with higher 
antibody responses to CSP also had higher responses 
to the N and C-terminal regions of the antigen (Fig. 2a). 
Given that the NANP repeat region and the C-terminus 
(PF16 peptide) represent distinct antigenic regions of 
the CSP with little overlap, the degree to which antibody 
responses to these respective regions fulfilled the condi-
tion of additivity, that the antibody concentration spe-
cific to a full-length antigen is the sum of the antibody 
concentrations to antigens representing its component 
parts, was evaluated. The condition of additivity in anti-
body responses is defined in greater detail in Additional 
file  1. In short, antibody responses to component anti-
gens (such as NANP and PF16) are additive, if the anti-
body response to the full-length antigen (CS), in terms of 
end-point ELISA titre, can be modelled as a linear combi-
nation of the antibody titres to the component antigens. 
Likewise, if CS titres cannot be modelled using NANP 
Fig. 1 Antibody responses stratified by protection status. Endpoint ELISA antibody titres are shown for recombinant full‑length CS (a), NANP repeat 
peptide (b), and the C‑terminal PF16 peptide (c) for non‑protected (NP) and protected (P) individuals. p value determined using Student’s t test
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and PF16 titres, that means the condition of additivity is 
not met. Reasons for why additivity may not be observed 
include: (1) antibodies bind to more than one compo-
nent simultaneously; (2) competition between antibodies 
of different epitopes; and, (3) epitopes in the full-length 
antigen that are not present in the component antigens.
Using linear regression, the following model was fit: CS 
titre = β1 × NANP titre + β2 × PF16 titre, and obtained 
values of β1 =  20.5 and β2 =  389. The model CS titres 
showed strong agreement with the experimental CS 
titres (Fig. 2b), suggesting that the condition of additivity 
between NANP titres, PF16 titres, and CS titres is met. 
The most straightforward interpretation of this result is 
that (1) the epitope regions corresponding to the NANP 
and PF16 antigens capture the CS response in its entirety; 
and, (2) CS antibodies bind to either the NANP repeat 
region or the C-terminal region, but not both. Indeed, 
an inverse relationship was found between the relative 
response to the NANP peptide and the PF16 peptide, rep-
resented by NANP:CS and PF16:CS titre ratios (Fig. 2c) 
that was statistically significant (p  <  0.01), consistent 
with the theory that CS response can be described as the 
sum of the NANP and PF16 responses. Furthermore, the 
observed additive relationship between the repeat region 
and C-terminal antibody responses suggests that the 
NANP and PF16 peptides present the relevant epitopes, 
in the appropriate conformation, as they are found in the 
full-length CS antigen.
Opsonization activity
Given the lack of a well-defined correlate of protection 
based on antibody titres alone, the functional activity of 
the antibody response was characterized in terms of its 
opsonization ability using an assay that measures the 
antibody-mediated phagocytosis of CSP-coated fluores-
cent beads by the human monocytic THP-1 cell line. Fol-
lowing a 2-h incubation with serial dilutions of a serum 
sample, the CSP-coated beads were incubated with 
THP-1 cells for 45  min. Flow cytometry of the THP-1 
cells following incubation with CSP-coated beads shows 
three distinct populations: cells that have not carried 
out phagocytosis (M0), cells that have phagocytosed one 
bead (M1), and cells that have phagocytosed two or more 
beads (M2). The level of phagocytosis for each sample 
was defined as the number of M2 cells (Mfreq), and the 
mean fluorescence intensity of M2 cells (MFI). Mfreq and 
MFI measures from M2 cells were used to ensure that 
the opsonization results reflected the most phagocyti-
cally active cells, but overall, a high correlation was found 
between Mfreq and MFI measures determined from M1 
and M2 cells (R2 of 0.85 for Mfreq and 0.89 for MFI, see 
Additional file  2). Figure  3 shows representative data 
from a control (no antibodies) and CSP-specific antibody 
samples at a single serum dilution. It is important to note 
that the histogram shows clear peaks for M0, M1 and M2 
populations demonstrating that the assay is capable of 
detecting distinct sub-populations of cells with respect to 
the number of phagocytosed beads. This represents a sig-
nificant improvement over a previous method developed 
by Schwenk et al. [21], which was not sensitive enough to 
detect a distinct sub-population of phagocytosing cells, 
requiring them to use a user-defined cut-off for fluores-
cence intensity to quantify the number of cells that car-
ried out phagocytosis.
The use of the Mfreq and MFI metrics enabled the descrip-
tion of phagocytosis activity in terms of (1) the frequency 
Fig. 2 CSP antibody epitope fine specificity. a Endpoint ELISA antibody titres to NANP and PF16 peptides compared against ELISA antibody titres 
to recombinant full‑length CS antigen (CS). b Additive model of CS antibody titres as a linear combination of NANP and PF16 ELISA antibody titres 
compared to ELISA antibody titres to CS. The following model was fitted using linear regression: CS titre = β1 × NANP titre + β2 × PF16 titre, and 
obtained values of β1 = 20.5 and β2 = 389. c Relative antibody responses shown as NANP:CS antibody titre ratio and PF16:CS antibody titre ratio. R2 
values from a Pearson correlation are shown if the statistically significance is at a cut‑off of p < 0.01
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(the number of phagocytically active cells); and, (2) the inten-
sity (the level of phagocytic activity of the cells, proportional 
to the number of CSP-coated beads taken up), respectively. 
Each of these four data points was measured at serial dilu-
tions ranging from 1:100 to 1:62,500, and used these data to 
generate an opsonization titre for each subject that corre-
sponds to the dilution at which 60 % of peak opsonization is 
observed. The availability of two data sets (Mfreq and MFI) 
results in calculation of two different opsonization titres. 
Representative data and fitted curves are shown for exam-
ples of low, medium and high opsonization titre subjects 
using Mfreq and MFI measures are shown in Fig. 4.
Next, the relationship between functional activity (as 
measured by Mfreq and MFI opsonization titres) and 
serological response (as measured by titres to the various 
regions of the CSP) (Fig. 5a) was investigated. The Mfreq 
opsonization titre was found to be highly correlated with 
anti-CSP antibody titre, but that MFI opsonization titre 
was not (Pearson correlation coefficients of 0.63 and 
0.47), suggesting that the amount of CSP-specific anti-
bodies in a given sample plays a much stronger role in 
determining the frequency of phagocytosis than the level 
of phagocytic activity.
Antibody fine‑specificity and opsonization activity
Given the correlation between CSP-specific antibody 
titres and opsonization titres, the degree to which anti-
body response to a particular region of the CSP anti-
gen, such as the central NANP repeat, or the C-terminal 
region, was predominantly responsible for opsonization 
activity was explored. The opsonization titre determined 
by both the Mfreq and MFI was compared with the 
ELISA antibody titre to full-length CSP, the NANP repeat 
peptide, and the PF16 peptide (Fig. 5b, c).
Surprisingly, no correlation was found between the 
antibody titres to the NANP repeat region and opsoniza-
tion titres for either the Mfreq or MFI measure. Due to 
the additive nature of NANP and C-terminal PF16 anti-
bodies to the full-length anti-CSP antibody response, this 
finding suggested that the phagocytic activity was medi-
ated by antibodies recognizing epitopes outside the cen-
tral repeat region. A subsequent comparison between the 
PF16 antibody titres and both Mfreq and MFI opsoniza-
tion titres showed a high correlation (Pearson correlation 
coefficient of 0.65 and 0.59, for Mfreq and MFI titres, 
respectively). This correlation was higher than that of the 
full-length anti-CSP response, confirming that antibod-
ies binding to the C-terminal region of CSP are largely 
responsible for opsonization, and that NANP antibodies 
are non-opsonizing.
Opsonization activity, fine specificity and protection
The opsonization titres for both Mfreq and MFI were 
stratified based on the observed protection. Overall, 
there was no significant difference in opsonization titres 
between protected and non-protected subjects from the 
RTS,S vaccine study (Fig.  6). However, unexpectedly, 
there was a trend towards lower opsonization titres in 
protected subjects.
To explore the relationship between protection, phago-
cytic activity and antibody titres to CSP epitopes, a meas-
ure called the opsonization index was created, which is 
the opsonization titre normalized by the full-length anti-
CSP antibody titre. Assuming that opsonization activity 
of a serum sample is mediated by CSP-specific antibod-
ies, the opsonization index measures the efficiency with 
which a given concentration of anti-CSP antibodies in a 
serum sample mediates opsonization. The opsonization 
Fig. 3 Flow cytometry to measure antibody‑mediated phagocytosis in THP‑1 cells. Example histograms of THP‑1 cells incubated with CSP‑coated 
NeutrAvidin beads. Markers capture either cells that have taken up at least one bead and thus are fluorescent positive (M1) or cells that have taken 
up two or more beads (M2). The control is a serum pool from malaria naïve US donors, CSP‑specific is a serum pool that is used as positive control 
by the Malaria Serology laboratory at WRAIR
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index, calculated using either Mfreq or MFI, was found 
to be significantly lower in protected subjects than in 
non-protected subjects (p  <  0.05 and p  <  0.01, respec-
tively) (Fig. 7a, b). This led to the unexpected conclusion 
that protected individuals have lower relative opsoniza-
tion activities than non-protected individuals.
Since the fine-specificity analysis suggested opsoni-
zation activity of anti-CSP antibodies was primarily 
mediated by C-terminal antibodies and not NANP anti-
bodies (Fig.  5), the ratio of PF16 versus NANP-specific 
antibodies of protected and non-protected subjects was 
compared. The results revealed that protected individu-
als had a lower PF16:NANP antibody titre ratio than 
non-protected subjects (Fig.  7c). This indicated that 
protected individuals not only have a higher absolute 
NANP response, but also a high relative NANP response 
(and low relative C-terminal response), and that this 
NANP-biased response is linked to both protection 
and a lower opsonization activity. One possible expla-
nation is that C-terminal antibodies inhibitory and/or 
otherwise negatively interfere with protection, another 
is that the fine specificity of the antibody response is a 
surrogate measure of an, as-of-yet, unidentified protec-
tive mechanism.
The epitope fine specificity or relative opsonization 
activity was analyzed to determine if it could add any 
value to distinguishing between protected and non-pro-
tected subjects in addition to the previously discovered 
correlate for NANP titres. Performing single-variable and 
two-variable ANOVA analysis to distinguish between 
protected and non-protected subjects demonstrated 
that including either opsonization index or PF16:NANP 
ratio (p value of 0.0002 and 0.002, respectively) with the 
NANP titre increases the statistical significance (Table 1). 
This indicates that the relative opsonization activity and 
epitope fine specificity provide additional value in dis-
tinguishing protected from non-protected subjects com-
pared to using NANP titres alone.
Overall, the results suggest that not only are pro-
tected individuals characterized by higher absolute 
antibody titres to NANP, but that they also show sys-
tematic differences in epitope fine specificity (expressed 
as PF16:NANP ratio) and opsonization activity (Fig.  8). 
Specifically, the study reveals that protected subjects are 
Fig. 4 Representative opsonization activity and fitting. Representative data for opsonization activity at serial dilutions (1:100, 1:500, 1:2500, 1:12,500, 
1:62,500) for two measures of opsonization: the frequency of cells undergoing phagocytosis (Mfreq, top) and the mean fluorescence intensity (MFI, 
bottom) of cells undergoing phagocytosis. Opsonization activity (circles) is shown after subtracting pre‑immune serum activity. Examples of low 
(left), medium (middle), and high (right) opsonization titres are shown. The four‑parameter curve fitted to the data is shown in red, the horizontal 
line indicates the opsonization activity at 60 % of maximum activity, and the vertical line indicates the log dilution corresponding to 60 % maximum 
activity, as determined by the fitted curve
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characterized by high relative NANP titres and low rela-
tive opsonization activity.
It is possible that if a measure, such as CS titre, were 
positively associated with protection, then an immune 
measure based on its inverse (CS titre)−1, would be 
negatively associated with protection, by default. Statis-
tical analyses were carried out to ensure that opsoniza-
tion activity provides some added value in the measure 
of opsonization index (opsonization activity divided by 
CS titres) over the simple inverse measure of (CS titre)−1 
alone. A 1-factor ANOVA using (CS titre)−1 showed no 
significant difference with respect to protection (p = 0.33) 
(compared to p  =  0.004 for opsonization index), and 
a 2-factor ANOVA using (CS titre)−1 and NANP titre 
showed no added improvement from NANP titre alone 
(p = 0.02 for both) in distinguishing protected from non-
protected individuals. This analysis shows the negative 
association between opsonization index and protection is 
not simply because it is a function of an inverse measure.
Discussion
RTS,S/AS01 has been evaluated in several trials around 
the world and is on track to become the first licensed 
malaria vaccine in the world. As is the case for most other 
vaccines, no definite functional correlate of protection is 
known for RTS,S/AS01; most of the uncertainty related 
to other vaccines is associated with the contribution of 
cellular responses to protection [6]. In case of RTS,S/
AS01-mediated protection, CD4+ responses and anti-
CSP antibodies have both been identified as surrogate 
markers of protection with antibodies [7]. This provides a 
strong rationale for further analysing the biological activ-
ity of these vaccine-induced responses.
The present study demonstrates for the first time the 
relationship between antibody titres to various regions 
of the CSP, the contribution of epitope specific antibod-
ies to the biological function (i.e., phagocytic activity in 
this study) and the underlying protective status of the 
samples. The current study has generated several key 
findings: (1) ELISA titres to the CSP central repeat region 
were significantly higher in protected individuals; (2) no 
differences in the overall ELISA titres to C-terminus or 
full-length CSP were detected; (3) the assessment of the 
opsonization titre per se did not yield a statistically sig-
nificant difference between protected and non-protected 
individuals; (4) calculation of the opsonization index 
(which is a function of phagocytic activity and ELISA 
titres) allowed the distinction between protected and 
Fig. 5 Scatterplot of opsonization titres and ELISA antibody titres. Scatterplots comparing Mfreq opsonization titre (top) and MFI opsonization (bot-
tom) with endpoint ELISA titres for CS (a), NANP (b), and PF16 (c) antigens. The Pearson correlation coefficient (R2) and statistical significance (p) is 
shown
Page 9 of 12Chaudhury et al. Malar J  (2016) 15:301 
non-protected subjects; (5) unexpectedly, the opsoniza-
tion index was inversely correlated with protection; (6) 
phagocytic activity is mediated by C-terminal antibodies 
and not repeat specific antibodies; (7) the predictive value 
of repeat specific ELISA titres or the ratio of PF16:NANP 
titres is lower than when using the opsonization index; 
and, (8) the ability to predict protection is highest when 
ELISA titres are combined with the opsonization index. 
One study has previously attempted to assess the phago-
cytic activity of RTS,S-induced antibodies, and although 
they reported a modest association between phagocytic 
activity and protection, their findings were limited by 
poor sensitivity of the assay [21]. Specifically, the low 
sensitivity in that study required a user-defined cut-off to 
be used to distinguish phagocytic from non-phagocytic 
cells. Beyond differences in methodology and reported 
opsonization measures, differences in the respective 
RTS,S clinical trials used in this previous study [21] and 
the current study, such as with immunization regimen 
and adjuvant conditions, preclude a direct comparison of 
the results.
The observation that repeat-specific antibodies were 
not contributing to the phagocytic activity measured in 
immunized subjects is a novel finding that requires fur-
ther investigations into the underlying cause. The find-
ings also indicate that a deeper understanding of the 
role of C-terminal antibodies in protection is needed. 
Studies in pre-clinical models have revealed that CSP 
C-terminal antibodies can play a crucial role in protec-
tion [22]. Previous work by the authors, employing a 
Fig. 6 Opsonization titres separated by protection. Opsonization titres calculated from Mfreq (a) and MFI (b) opsonization activity measures is 
shown for non‑protected (NP) and protected (P) individuals
Fig. 7 Opsonization index and epitope fine specificity separated by protection. Mfreq opsonization index (a), MFI opsonization index (b), and log 
ratio of PF16 antibody titres to NANP antibody titres (c) for non‑protected (NP) and protected (P) individuals. p values determined using Student’s t 
test
Table 1 ANOVA statistics for  protected vs non-protected 
subjects
Type Variables p value
1‑Factor NANP titer 0.02
1‑Factor Opsonization index 0.004
1‑Factor PF16:NANP ratio 0.04
2‑Factor Opsonization index, NANP titer 0.0002
2‑Factor PF16:NANP ratio, NANP titer 0.002
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molecular adjuvant based on the complement factor 
C3d, demonstrated that the loss of C-terminal specificity 
in the overall humoral response to CSP greatly impaired 
protective efficacy [22]. The C-terminus of CSP contains 
several important functional elements, such as adhesion 
motifs for complement, thrombospondin and properdin. 
The properdin binding sequence, found in all Plasmo-
dium species, may modulate susceptibility to infection 
[23–25]. The C-terminus has also been implicated in the 
initial entry of the sporozoites into hepatocytes [26] and, 
therefore, antibodies against this CSP-region play a role 
in protection [22, 27, 28]. A separate study by the authors 
has demonstrated that the parasites target this region of 
the CSP in an attempt to deviate the immune response 
[22], thus further supporting the hypothesis that this is 
a crucial region for the function and ultimately survival 
of the parasite. Therefore, an in-depth analysis of the 
biological function of C-terminal antibodies is needed 
before drawing conclusions regarding the overall impor-
tance in vaccine-induced protection.
The finding that phagocytosis is inversely correlated 
with protection was unexpected and merits further study 
with a larger sample size. The question remains: What 
is the biological consequence of the antibody-mediated 
uptake of the sporozoite into the phagocyte? Additional 
studies addressing this question are needed to determine 
whether Plasmodium employs similar immune escape 
strategies as has been reported for Leishmania (reviewed 
in [29]). Metacyclic promastigotes of Leishmania express 
a specialized protein, namely gp63, which quickly con-
verts the complement factor C3b to C3bi, resulting 
in a preferential interaction between the opsonized 
promastigote and Complement receptor 3 (CR3) (rather 
than Complement receptor 1) [30]. The binding to CR3 
still results in phagocytosis, but prevents the oxidative 
burst response during phagocytosis [31].
Beyond the limited sample size, there are a number of 
limitations of the present study in assessing the biologi-
cal phagocytic activity of the RTS,S antibody response. 
There is mounting evidence that in  vitro assays have 
only a limited ability to forecast the precise Fc effec-
tor mechanisms engaged by opsonizing antibodies since 
these assays are typically performed with monocytic 
cells [15, 16]. In contrast, in  vivo, there is a wide range 
of immune cells competing with each other for the bind-
ing of immune complexes [32]. Most leukocytes express 
several Fc receptors and these can be classified based on 
their biological activity: type I receptors that provide an 
activating signal for the cell, while type II receptors pro-
vide a modulatory response [33]. Which Fc receptors are 
engaged by immune complexes is not solely governed 
by the isotype of the antibody, but also by the confor-
mational state of the antibody (i.e., the glycosylation 
pattern). Moreover, some of these receptors are differ-
entially expressed on immune cells, e.g., NK cells express 
only type I receptors and are, therefore, activated when 
immune complexes bind. In contrast, B cell express only 
type II receptors and, thus, binding of immune com-
plexes to the Fc receptor without simultaneous ligation of 
the BCR results in a pro-apoptotic signal [34]. Moreover, 
high antibody titres and immune complexes can result in 
immune dysfunction by interfering with effector func-
tions [35]. Finally, given the role of epitope density and 
arrangement in opsonophagocytosis, it is possible that 
Fig. 8 Opsonization index and epitope fine specificity combined with NANP antibody response. a Scatterplot of antibody fine specificity, based 
on PF16:NANP antibody titre ratios compared with antibody titre to NANP for non‑protected (NP) and protected (P) individuals. b Scatterplot of 
MFI opsonization index and NANP antibody titre for non‑protected and protected individuals. A 2‑way ANOVA shows that both pairs of immune 
measures significantly distinguish between protected and non‑protected subjects (p = 0.002 and p = 0.0002, for PF16:NANP and NANP titre, and 
MFI opsonization index and NANP titre, respectively)
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there are differences in CSP presentation or density in 
sporozoites and in CSP-coated beads.
Although the current study cannot determine the ulti-
mate biological consequences for sporozoite opsonization, 
it provides opsonization as a surrogate marker of protec-
tive immunity based on measuring the phagocytic activity 
mediated by vaccine (RTS,S)-induced antibodies, specifi-
cally antibodies targeting the CSP C-terminus. Typically, 
surrogate markers of protection are indicative of a pro-
tective response, but the activity measured is per se not 
involved in the mediation of protection [6]. Future studies 
may address the discrepancies between in vitro and in vivo 
assay systems by utilizing peripheral blood mononuclear 
cells of each study subject to measure the phagocytic activ-
ity within these individuals, thus accounting for the heter-
ogeneity of phagocytic cells as well as any polymorphisms 
in the Fc receptors of the respective subjects.
Conclusion
The current study demonstrates that limiting serologi-
cal evaluations of vaccine studies for malaria, and likely 
also other infectious diseases, to the measurement of 
antibody titres may fail to predict vaccine efficacy unless 
functional assays are incorporated into the assessment. 
Linking the fine specificity of the humoral response with 
the magnitude and functional activity of the antigen-spe-
cific antibodies will have the greatest potential for suc-
cess. By employing a novel phagocytosis assay, this study 
unveiled an unexpected inverse correlation between 
phagocytosis and protection against malaria mediated by 
RTS,S-induced antibodies.
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